{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://celldex.com/#organization",
      "name": "Celldex Therapeutics",
      "url": "https://celldex.com/",
      "description": "Home - Celldex Therapeutics Skip to content Menu Close --> Our Company Pipeline Science Investors Careers Contact Pioneering new horizons in immunology to deliver life-changing therapies. Latest News May 8, 2025 Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update May 5, 2025 Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease --> Our lead program barzolvolimab is a humanized monoclonal antibody inhibitor of KIT, a key receptor tyrosine kinase required for the function and survival of mast cells, which play a central role in the onset and progression of many se"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/celldex-therapeutics#asg",
      "name": "Celldex Therapeutics ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/celldex-therapeutics",
      "isPartOf": {
        "@id": "https://celldex.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}